BackRosetta Genomics Overview
Rosetta Genomics Ltd.

Rosetta Genomics Return on Equity

Rosetta Genomics (ROSGQ) has a ROE of -1298.18%, below the sector sector average of 10.27%.

Get informed when a big investor buys or sells

+ Follow

ROE

-1298.18%

Return on Equity

-1298.18%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Rosetta Genomics (ROSGQ) FAQ

Rosetta Genomics (ROSGQ) currently reports a ROE of -1298.18%. That is below the sector sector average of 10.27%. Use the charts on this page to explore Rosetta Genomics's ROE history and peer comparisons.

Rosetta Genomics's ROE of -1298.18% is lower than the its sector sector average of 10.27%. That is roughly 12746.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Rosetta Genomics's current -1298.18% should be judged against industry norms (sector average: 10.27%) and against ROSGQ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -1298.18%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 10.27%. From there, open related valuation or income-statement pages for Rosetta Genomics, and consider following ROSGQ for alerts when major investors trade the stock.

Questions & Answers